BridgeMD
New treatment option for Medulloblastoma, WNT-activated
Official title Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
ClinicalTrials.gov ID: NCT04474964
What this study is testing
- What it's testing
- This clinical study is going to be done on a type of brain tumor in children called Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and have the best outcomes in terms of survival.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 3 to 16
You may be able to join if
- Age more than 3 years and less than 16 years.
- Newly diagnosed WNT pathway medulloblastoma.
- Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
- No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain/spine and lumbar puncture for CSF...
- Fit for initiation of adjuvant treatment within 6-weeks of surgery
You likely can't join if
- Age Less than 3 and more than 16 years.
- Molecular subgroup other than WNT pathway.
- Post-surgery residual disease more than 1.5cm2 on post-operative imaging.
- Evidence of any metastatic disease in the brain, spine or CSF.
- Previous history of radiotherapy or chemotherapy prior to study enrollment.
- Not fit for initiation of adjuvant treatment within 6 weeks of surgery.
See the full eligibility criteria
- Age more than 3 years and less than 16 years.
- Newly diagnosed WNT pathway medulloblastoma.
- Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
- No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain/spine and lumbar puncture for CSF cytology.
- Fit for initiation of adjuvant treatment within 6-weeks of surgery
- Age Less than 3 and more than 16 years.
- Molecular subgroup other than WNT pathway.
- Post-surgery residual disease more than 1.5cm2 on post-operative imaging.
- Evidence of any metastatic disease in the brain, spine or CSF.
- Previous history of radiotherapy or chemotherapy prior to study enrollment.
- Not fit for initiation of adjuvant treatment within 6 weeks of surgery.
- Not willing for consent/assent.
The study team makes the final eligibility decision.
Where it's taking place
- Mumbai, Maharashtra, India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 3 years to 16 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mumbai, Maharashtra, India. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.